Upadacitinib
A daily JAK-inhibitor tablet used for moderate to severe Crohn's when other advanced treatments have not worked or are unsuitable.
Also called: rinvoq, upa, upadacitnib, upadacitanib
Related words jak inhibitor
Topics Medicines
A daily JAK-inhibitor tablet used for moderate to severe Crohn's when other advanced treatments have not worked or are unsuitable.
Also called: rinvoq, upa, upadacitnib, upadacitanib
Related words jak inhibitor
Topics Medicines
Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.
Sources
Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.
Sources
NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.
Sources
A guide to upadacitinib (Rinvoq), a tablet that belongs to the JAK inhibitor group of targeted medicines. It explains how blocking JAK proteins calms the immune response, what trials showed, and the side effects and safety checks involved.
Topics Medicines Biologics and newer medicines
Jargon explained JAK inhibitor Janus kinase targeted medicine small molecule
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics Medicines Immunosuppressants Research
Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response
NICE's appraisal recommending upadacitinib (Rinvoq), a tablet, for adults with moderate to severe Crohn's disease after a biologic has not worked, stopped working or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Medicines Biologics and newer medicines
Jargon explained JAK inhibitor small molecule TNF-alpha inhibitor
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics Medicines Surgery Monitoring
Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics Biologics and newer medicines Research
Jargon explained network meta-analysis relative risk number needed to treat biosimilar
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics Biologics and newer medicines Medicines
Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy
Everyone with Crohn's is advised not to smoke. The charity explains that smoking raises the risk of getting Crohn's and can make it worse, can limit which medicines you are offered (some newer tablets are generally not given to smokers), and matters before surgery. It summarises the early research on vaping and passive smoking and where to get help to stop.
Topics Living well
Jargon explained smoking cessation JAK inhibitor passive smoking